Hussman Strategic Advisors Inc. Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hussman Strategic Advisors Inc. acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,500 shares of the medical equipment provider’s stock, valued at approximately $939,000.

Other large investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter worth about $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus in the 4th quarter valued at about $27,000. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. lifted its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new stake in Lantheus in the 3rd quarter valued at about $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $80.88 on Friday. Lantheus Holdings, Inc. has a 1 year low of $56.06 and a 1 year high of $126.89. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of 13.46 and a beta of 0.44. The company’s 50 day simple moving average is $90.60 and its 200 day simple moving average is $97.20.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.